Topical CBD Formulation with TRPM8 Agonists for Transdermal Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for transdermal delivery of cannabidiol (CBD) lack effectiveness in targeting specific areas for pain relief, particularly for muscle, joint, and connective tissue pain, and there is a need for improved formulations that can efficiently deliver CBD to cell membrane receptors and intra-cellular sites.
Innovation Solution
A topical formulation combining CBD with high concentrations of TRPM8 agonists, such as menthol, and a carrier material, with specific weight ratios of CBD to THC and TRPM8 agonists, to enhance transdermal delivery and pain relief, including the use of camphor and lipophilic materials for improved efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If transdermal delivery of CBD is used to target specific areas for pain relief, then pain relief effectiveness is improved, but delivery efficiency to cell membrane receptors and intra-cellular sites remains insufficient
Solution Approach 1:
The patent modifies the chemical parameters of the formulation by incorporating TRPM8 agonists (menthol, camphor, eucalyptus oil) at specific concentrations and ratios with CBD. This parameter change enhances the formulation's ability to penetrate skin barriers and reach target receptors, thereby improving delivery efficiency while maintaining pain relief effectiveness.
Solution Approach 2:
The invention creates a composite topical formulation combining CBD with TRPM8 agonists and carrier materials. This composite approach synergistically enhances the penetration and delivery of CBD to cell membrane receptors and intra-cellular sites, resolving the contradiction between reliability of pain relief and productivity of delivery efficiency.
2Reliability
If high concentrations of TRPM8 agonists are added to enhance pain relief, then therapeutic efficacy is improved, but formulation complexity increases
Solution Approach 1:
The patent merges multiple TRPM8 agonists (menthol, camphor, eucalyptus oil) into a single integrated formulation with CBD. This combining approach achieves enhanced therapeutic efficacy through synergistic effects while managing formulation complexity by establishing specific concentration ranges and ratios for each component.
Solution Approach 2:
The invention optimizes the concentration parameters of TRPM8 agonists within specific ranges (e.g., menthol 0.1-10%, camphor 0.1-10%) to achieve maximum therapeutic efficacy while controlling formulation complexity. The defined weight ratios between components provide clear manufacturing guidelines that simplify production.
3Reliability
If specific weight ratios of CBD to THC and TRPM8 agonists are maintained, then pain relief effectiveness is improved, but manufacturing precision requirements increase
Solution Approach 1:
The patent establishes specific parameter ranges for weight ratios (CBD:THC ratio of 5:1 to 100:1, TRPM8 agonist:CBD ratio of 1:1 to 10:1) that balance pain relief effectiveness with achievable manufacturing precision. These ranges provide flexibility in production while maintaining therapeutic efficacy.
Solution Approach 2:
The invention applies different quality standards to different components of the formulation. While CBD and TRPM8 agonists require precise ratio control for optimal efficacy, the carrier materials and other excipients have more flexible specifications. This localized quality approach maintains pain relief effectiveness while reducing overall manufacturing precision requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation provides significant pain relief for conditions like arthritis and peripheral neuropathic pain, with the high TRPM8 agonist concentrations effectively blocking pain receptors, leading to enhanced therapeutic outcomes compared to existing formulations.
Implementation Method 1
the formulations include at least one, and typically at least two, or at least three, agonists of a transient receiver potential melastatin cation channel member 8 (TRPM8)
Implementation Method 2
transdermal delivery of cannabinoids enables specific areas of the body (e.g., of a muscle or joint) to be targeted for treatment
Implementation Method 3
the formulations have a high weight ratio of CBD to (−)-trans-Δ9-tetrahydrocannabinol (THC)
Data Source
AI summary
Methods and formulations for providing efficacious pain relief by transdermal delivery of cannabidiol (CBD), the formulations having a high weight ratio of CBD to (−)-trans-Δ9-tetrahydrocannabinol (THC).